HMBD-002, an anti-VISTA monoclonal antibody, is currently under clinical evaluation in triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC) patients (NCT05082610). The gene discussed is VSIR; the disease is non-small cell lung carcinoma.